fulvestrant has been researched along with finasteride in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alaoui-Jamali, MA; Alpert, L; Chan, TW; Huynh, H; Ng, CY | 1 |
| Arzate, H; Chimal-Monroy, J; Enríquez, J; García, GA; Herrero, B; Larrea, F; Lemus, AE; Pérez-Palacios, G | 1 |
| Campelo, AE; Cutini, PH; Massheimer, VL | 1 |
1 review(s) available for fulvestrant and finasteride
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for fulvestrant and finasteride
| Article | Year |
|---|---|
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate.
Topics: 5-alpha Reductase Inhibitors; Animals; Blotting, Northern; Cell Division; Drug Synergism; Enzyme Inhibitors; Epithelial Cells; Estradiol; Estrogen Antagonists; Finasteride; Fulvestrant; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Organ Size; Phosphorylation; Prostate; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Receptor, IGF Type 1; Statistics, Nonparametric | 2001 |
The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites.
Topics: 5-alpha Reductase Inhibitors; Animals; Calcification, Physiologic; Calcium; Cell Differentiation; Cell Proliferation; Cells, Cultured; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Finasteride; Fulvestrant; Humans; Levonorgestrel; Norethindrone; Osteoblasts; Osteocalcin; Phenols; Progesterone Congeners; Rats; Rats, Wistar | 2007 |
Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol.
Topics: 5-alpha Reductase Inhibitors; Anastrozole; Androgen Antagonists; Animals; Aorta; Aromatase Inhibitors; Cell Adhesion; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Estradiol; Estrogen Antagonists; Female; Finasteride; Flutamide; Fulvestrant; Monocytes; Myocytes, Smooth Muscle; Nitric Oxide; Nitriles; Rats; Rats, Wistar; Testosterone; Triazoles | 2012 |